Table 4.
Dosimetric results for CTV and organs at risk shown as differences (mean [range]) between the breath‐hold scenario or worst‐case scenario and the planned dose/volume parameters. Shown for both 3 mm and 5 mm setup robustness settings
| Planned | Planned – Breath‐hold scenario | Planned – Worst‐case scenario | ||||
|---|---|---|---|---|---|---|
| Median (range) | Median (range) | Median (range) | ||||
| 3 mm setup robustness | 5 mm setup robustness | 3 mm setup robustness | 5 mm setup robustness | 3 mm setup robustness | 5 mm setup robustness | |
| CTV | ||||||
| D98% (Gy) | 59.4 (58.6–59.9) | 59.0 (58.2–59.5) | −0.5 (−5.4–1.0) | −0.1 (−4.1–2.0) | 0.0 (−8.0–1.3) | 0.0 (−8.8–0.8) |
| D1cc (Gy) | 62.8 (61.7–62.9) | 62.3 (61.1–62.9) | 0.6 (−0.5–6.1) | 0.9 (−0.3–4.6) | 0.0 (−5.2–1.8) | 0.4 (−0.2–1.7) |
| Heart | ||||||
| Dmean (Gy) | 1.2 (0.1–5.1) | 1.4 (0.2–6.0) | 0.0 (−0.1–0.3) | 0.0 (−0.2–0.2) | 0.0 (−0.2–0.2) | 0.0 (−0.2–0.2) |
| Lungs | ||||||
| Dmean (Gy) | 4.0 (2.0–7.1) | 4.5 (2.3–8.2) | 0.0 (−0.3–0.2) | 0.0 (−0.3–0.2) | 0.0 (−0.3–0.5) | 0.0 (−0.9–0.5) |
| V20 Gy (%) | 7.8 (3.9–13.7) | 8.8 (4.4–16.7) | 0.0 (−0.5–0.3) | 0.0 (−0.6–0.3) | 0.0 (−1.4–0.6) | 0.0 (−1.6–1.2) |
| Esophagus | ||||||
| V35 Gy (%) | 0.0 (0.0–12.4) | 0.0 (0.0–14.3) | 0.0 (−0.1–0.3) | 0.0 (−0.4–0.5) | 0.0 (−0.9–0.9) | 0.0 (−0.4–1.1) |
| Spinal Cord | ||||||
| D0.1cc (Gy) | 0.1 (0.1–15.3) | 0.1 (0.0–22.0) | 0.0 (−0.1–1.0) | 0.0 (−0.4–1.4) | 0.0 (−1.9–1.6) | 0.0 (−3.2–7.5) |
CTV, clinical target volume; D98%, dose given to 98% of volume; D1cc, dose given to 1 cc of volume; Dmean, mean dose; V20, volume receiving 20 Gy; V35, volume receiving 35 Gy; D0.1cc, dose given to 0.1cc of volume.